256 related articles for article (PubMed ID: 23022995)
1. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
[TBL] [Abstract][Full Text] [Related]
2. CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression.
Chen S; Wang Y; Chen L; Xia Y; Cui J; Wang W; Jiang X; Wang J; Zhu Y; Sun S; Zou Y; Gong Y; Shi B
Int J Biochem Cell Biol; 2021 Jan; 130():105887. PubMed ID: 33227394
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
4. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
5. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
6. The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
Huang B; Cao K; Li X; Guo S; Mao X; Wang Z; Zhuang J; Pan J; Mo C; Chen J; Qiu S
J Exp Clin Cancer Res; 2011 Sep; 30(1):88. PubMed ID: 21955404
[TBL] [Abstract][Full Text] [Related]
7. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma.
Huang J; Dong B; Zhang J; Kong W; Chen Y; Xue W; Liu D; Huang Y
Tumour Biol; 2014 Jun; 35(6):5833-43. PubMed ID: 24609899
[TBL] [Abstract][Full Text] [Related]
8. GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.
Xue Y; Wu G; Liao Y; Xiao G; Ma X; Zou X; Zhang G; Xiao R; Wang X; Liu Q; Long D; Yang J; Xu H; Liu F; Liu M; Xie K; Huang R
Br J Cancer; 2014 Apr; 110(9):2250-60. PubMed ID: 24595000
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
11. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
Harshman LC; Choueiri TK
Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
[TBL] [Abstract][Full Text] [Related]
12. The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review.
Chen S; Zhu Y; Cui J; Wang Y; Xia Y; Song J; Cheng S; Zhou C; Zhang D; Zhang B; Shi B
Urol Oncol; 2017 Aug; 35(8):532.e15-532.e23. PubMed ID: 28427859
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
14. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.
Konda R; Sato H; Hatafuku F; Nozawa T; Ioritani N; Fujioka T
J Urol; 2004 Jun; 171(6 Pt 1):2166-70. PubMed ID: 15126778
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
17. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
Miyata Y; Kanetake H; Kanda S
Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth.
Inoue K; Karashima T; Chikazawa M; Iiyama T; Yoshikawa C; Furihata M; Ohtsuki Y; Shuin T
Virchows Arch; 1998 Dec; 433(6):511-5. PubMed ID: 9870683
[TBL] [Abstract][Full Text] [Related]
19. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
